Clinical trials: Mpox
Monkeypox Virus Infection
JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo
Mpox is a febrile rash illness caused by the monkeypox virus. Its natural occurrence in the DRC puts healthcare and frontline workers at high risk of acquiring monkeypox virus infections that can prevent them from performing work…
- Trial name
- NCT02977715
- Testing
- JYNNEOS (Liquid Formulation), JYNNEOS (Lyophilized Formulation)
- Where
- Democratic Republic of the Congo
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Colorectal Cancer, Monkey Pox
FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues
Colorectal cancer tissue sections were obtained according to the inclusion criteria. The formalin was used to immersed all cancer specimens. And tissues were cut to 5 μm thickness and placed on glass slides before staining.
- Trial name
- NCT05698082
- Testing
- Immunohistochemical staining with anti-FOS
- Where
- China
- Volunteers
- 120 people
- Sponsor
- xiaoliang Huang
Mpox
Monkeypox, Biology, Outcome, Transmission and Epidemiology -Prospective Follow-up of High-risk Contacts
With the MBOTE-CONTACT study, a detailed follow-up study of high-risk contacts of mpox patients will be done. The MBOTE-CONTACT study will be nested in the NIH-Funded PALM-007 clinical trial (NCT05559099) and the MBOTE project on…
- Trial name
- MBOTE-CONTACT (NCT06136117)
- Where
- Democratic Republic of the Congo
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Monkeypox
Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT
A cluster randomized controlled trial to determine if smallpox vaccine reduces secondary cases and symptom severity in persons exposed to mpox.
- Trial name
- SMART (NCT05745987)
- Testing
- Bavarian Nordic smallpox vaccine, Typhoid VI Polysaccharide Vaccine Injectable Solution
- Where
- 10 sites in Democratic Republic of the Congo, Nigeria and 1 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- McMaster University
Monkeypox
Tecovirimat for Treatment of Monkeypox Virus
The purpose of this study is to find out if tecovirimat is a safe and effective drug to treat monkeypox (mpox) in combination with standard of care (SOC).
- Trial name
- NCT05559099
- Testing
- Tecovirimat Oral Capsule
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 597 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkey Pox
Assessing the Preparedness and Knowledge of Pharmacists in the Current Monkeypox Outbreak
General objective: to measure the preparedness of pharmacists and medical interns about monkeypox Specific objectives: to evaluate the level of knowledge among pharmacists and medical interns about monkeypox treatment and nature…
- Trial name
- NCT05543577
- Testing
- Questionnaire
- Where
- Egypt
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beni-Suef University
Mpox
Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that…
- Trial name
- MPOX CARE (NCT06887556)
- Testing
- ELISA, Lateral flow assay
- Where
- Rwanda
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
Monkeypox (Mpox)
Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo
To evaluate the safety and immunogenicity of the MVA-SIBP vaccine using a double-blind, randomized, controlled, age de-escalation design conducted in Kinshasa, Democratic Republic of the Congo (DRC).
- Trial name
- NCT07253675
- Testing
- MVA-SIBP low dose, MVA-SIBP high dose, MVA-BN
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Mpox (Monkeypox)
Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only
The purpose of the PALM007 extension is to further characterize the clinical and natural history of mpox, and to provide standard of care (SOC) during the ongoing outbreaks.
- Trial name
- NCT06721585
- Testing
- Tecovirimat Oral Capsule [Tpoxx], Standard of Care (SOC)
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 328 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
Tecovirimat in Non-hospitalized Patients With Monkeypox
PLATINUM-CAN is a parallel collaborative trial linked with the sister trial PLATINUM led by Oxford University. PLATINUM-CAN is a multi-centre, randomized, placebo-controlled trial of Tecovirimat in non-hospitalized patients with…
- Trial name
- PLATINUM-CAN (NCT05534165)
- Testing
- Tecovirimat
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Marina Klein
Monkeypox (Mpox)
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
All participants will receive 2 vaccinations of the same dose of Modified Vaccinia Ankara Virus (MVA-BN) vaccine 4 weeks apart (standard regimen).
- Trial name
- NCT06549530
- Testing
- MVA-BN
- Where
- 3 sites in Democratic Republic of the Congo, Uganda
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Monkeypox, MPOX
Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus…
- Trial name
- NCT05784038
- Testing
- Viral genomic, Untargeted Metabolomics
- Where
- 3 sites in Brazil
- Volunteers
- 80 people
- Sponsor
- Hospital Israelita Albert Einstein
Monkeypox
Pilot Study to Detect Monkey Pox Virus in Sperm: POXSPERM
Given the current emerging epidemic of the MonkeyPox Virus (MPXV) and its route of transmission, the main objective of this pilot study is to characterize the presence of the MPXV in the semen of patients in the acute phase of…
- Trial name
- POXSPERM (NCT05629299)
- Testing
- Samples
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
Monkeypox
Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia
Background: Mpox is a zoonotic disease caused by the mpox virus (MPXV). It has been endemic in West and Central African countries.
- Trial name
- MPOX-COL (NCT06223919)
- Testing
- LC16m8
- Where
- 3 sites in Colombia
- Volunteers
- 8,686 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Colombia
Monkeypox
Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
This observational study has been designed to characterize humoral and cellular immune responses after vaccination against monkeypox (MKP) in HIV positive and negative individuals at high risk of MKP infection during the…
- Trial name
- NCT05562323
- Where
- 3 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Vaccinia
SIGA-246 to Treat Smallpox
This study will test an experimental antiviral drug called SIGA-246 for use against the smallpox virus (variola). Although smallpox has been universally eradicated, it could possibly be brought back as a bioweapon.
- Trial name
- NCT00303225
- Testing
- Vaccine: SIGA-246
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Smallpox, Monkeypox
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
The Aim: Study immunogenicity, confirm the safety and tolerability of different schedules of vaccination with "live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus"…
- Conditions
- Smallpox, Monkeypox, Cowpox, Vaccinia Virus Infection
- Trial name
- NCT05846243
- Testing
- VAC∆6 vaccine (10⁷ PFU), VAC∆6 vaccine (10⁶ PFU), Live Smallpox Vaccine
- Where
- 2 sites in Russia
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Monkey Pox
Efficacy and Acceptability of a Monkeypox Curriculum for Disproportionately Impacted Communities
The study team will create an online module via the REDCap platform. The module will include around 5 videos and several infographics covering the topics of symptoms, transmission, prevention, vaccination, and treatment of the…
- Trial name
- NCT05651581
- Testing
- Online module
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Monkeypox
Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
This study is to evaluate the long-term immunogenicity of a boost dose of MVA-BN vaccine
- Trial name
- M-BOOST-FR (NCT06885853)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Smallpox, Mpox
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
The goal of this study is to assess the safety, tolerability and immunogenicity of mRNA-1769 in healthy adult participants.
- Trial name
- NCT05995275
- Testing
- mRNA-1769
- Where
- 12 sites in United Kingdom
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.